GNOM vs. GSKH

Last updated Jun 24, 2026

GNOM (Global X Genomics & Biotechnology ETF) and GSKH (GSK plc ADRhedged ETF) are both Health & Biotech Equities funds - GNOM tracks the Solactive Genomics Index while GSKH tracks the GSK plc Local Shares Total Return. Both are passively managed. Over the past year, GNOM returned 61.83% vs 42.66% for GSKH. At a 0.31 correlation, their price movements are largely independent. GNOM charges 0.50%/yr vs 0.19%/yr for GSKH.

Performance

GNOM vs. GSKH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology ETF (GNOM) and GSK plc ADRhedged ETF (GSKH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GNOM achieves a 14.90% return, which is significantly higher than GSKH's 9.90% return.

GNOM

• 1D: 0.90%
• 1M: 12.22%
• YTD: 14.90%
• 6M: 11.42%
• 1Y: 61.83%
• 3Y*: 2.88%
• 5Y*: -11.06%
• 10Y*: —

GSKH

• 1D: 2.87%
• 1M: 2.94%
• YTD: 9.90%
• 6M: 10.56%
• 1Y: 42.66%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM vs. GSKH - Yearly Performance Comparison

	2026 (YTD)	2025
GNOM Global X Genomics & Biotechnology ETF	14.90%	13.76%
GSKH GSK plc ADRhedged ETF	9.90%	36.51%

Correlation

The correlation between GNOM and GSKH is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.33
Correlation (All Time) Calculated using the full available price history since Jan 7, 2025	0.31

Return for Risk

GNOM vs. GSKH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM

GNOM Risk / Return Rank: 68
GNOM Sharpe Ratio Rank: 76
GNOM Sortino Ratio Rank: 74
GNOM Omega Ratio Rank: 63
GNOM Calmar Ratio Rank: 71
GNOM Martin Ratio Rank: 58

GSKH

GSKH Risk / Return Rank: 51
GSKH Sharpe Ratio Rank: 53
GSKH Sortino Ratio Rank: 56
GSKH Omega Ratio Rank: 54
GSKH Calmar Ratio Rank: 51
GSKH Martin Ratio Rank: 41

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM vs. GSKH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and GSK plc ADRhedged ETF (GSKH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	GNOM	GSKH	Difference
Sharpe ratio: Return per unit of total volatility	2.28	1.64	+0.64
Sortino ratio: Return per unit of downside risk	3.11	2.43	+0.68
Omega ratio: Gain probability vs. loss probability	1.36	1.30	+0.05
Calmar ratio: Return relative to maximum drawdown	3.42	2.31	+1.11
Martin ratio: Return relative to average drawdown	9.81	6.06	+3.76

GNOM vs. GSKH - Sharpe Ratio Comparison

The current GNOM Sharpe Ratio is 2.28, which is higher than the GSKH Sharpe Ratio of 1.64. The chart below compares the historical Sharpe Ratios of GNOM and GSKH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

GNOM vs. GSKH - Drawdown Comparison

The maximum GNOM drawdown since its inception was -75.00%, which is greater than GSKH's maximum drawdown of -18.54%. Use the drawdown chart below to compare losses from any high point for GNOM and GSKH.

Drawdown Indicators

	GNOM	GSKH	Difference
Max Drawdown Largest peak-to-trough decline	-75.00%	-18.54%	-56.46%
Max Drawdown (1Y) Largest decline over 1 year	-18.17%	-18.54%	+0.37%
Max Drawdown (3Y) Largest decline over 3 years	-44.24%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-72.29%	—	—
Current Drawdown Current decline from peak	-52.52%	-11.62%	-40.90%
Average Drawdown Average peak-to-trough decline	-40.63%	-5.86%	-34.77%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.32%	7.06%	-0.74%

Volatility

GNOM vs. GSKH - Volatility Comparison

Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 9.34% compared to GSK plc ADRhedged ETF (GSKH) at 6.89%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than GSKH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GNOM	GSKH	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.34%	6.89%	+2.45%
Volatility (6M) Calculated over the trailing 6-month period	20.57%	18.67%	+1.90%
Volatility (1Y) Calculated over the trailing 1-year period	27.29%	26.14%	+1.15%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.68%	26.95%	+6.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	34.17%	26.95%	+7.22%

GNOM vs. GSKH - Expense Ratio Comparison

GNOM has a 0.50% expense ratio, which is higher than GSKH's 0.19% expense ratio.

Dividends

GNOM vs. GSKH - Dividend Comparison

GNOM's dividend yield for the trailing twelve months is around 1.20%, less than GSKH's 2.82% yield.

Position	TTM	2025	2024	2023	2022	2021	2020
GNOM Global X Genomics & Biotechnology ETF	1.20%	1.37%	0.00%	0.00%	0.00%	0.03%	0.14%
GSKH GSK plc ADRhedged ETF	2.82%	1.15%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both GNOM and GSKH in my portfolio?

GNOM and GSKH have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GNOM or GSKH?

GNOM has higher volatility (9.34%) compared to GSKH (6.89%). In terms of maximum drawdown, GNOM dropped -75.00% vs GSKH's -18.54%.

Which ETF is better, GNOM or GSKH?

On 1-year performance, GNOM leads with 61.83% vs 42.66% for GSKH. On fees, GSKH is cheaper at 0.19% per year. On volatility, GSKH has been the lower-risk option at 6.89%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, GNOM or GSKH?

Over the 1-year period, GNOM has performed better with a 61.83% return vs 42.66%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, GNOM or GSKH?

GSKH is cheaper with a 0.19% expense ratio, compared with 0.50% for GNOM.

Which ETF pays a higher dividend yield, GNOM or GSKH?

GSKH has the higher dividend yield at 2.82%, compared with 1.20% for GNOM.

What is the main difference between GNOM and GSKH?

GNOM tracks Solactive Genomics Index, while GSKH tracks GSK plc Local Shares Total Return. They also come from different issuers: Global X and ADRhedged. Their fees differ too: 0.50% for GNOM and 0.19% for GSKH.

Which has better risk-adjusted returns?

GNOM currently has the higher Sharpe Ratio (2.28 vs 1.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.